Illumina, Inc. (ILMN) Stock
ILMN Key Statistics
About Illumina, Inc.
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
CEO: Jacob Thaysen. Company website
ILMN — Frequently Asked Questions
What is the ILMN stock price today?
Illumina, Inc. (ILMN) trades at $212.93, down 0.92% on the day, as of Nov 12, 2026 09:20 UTC.
What is Illumina, Inc.'s market cap?
Illumina, Inc. has a market capitalisation of $32.20B, calculated from the live ILMN share price and shares outstanding.
What is the P/E ratio of ILMN?
ILMN trades at a trailing P/E of 36.59, from earnings per share of $5.82 over the last twelve months.
How much revenue does Illumina, Inc. make?
Illumina, Inc. generated revenue of $4.54B over the trailing twelve months, which puts the stock at 7.09 times sales.
What is the 52-week range for ILMN?
ILMN has traded between $112.65 and $309.35 over the past 52 weeks, and the last price is 31.2% below that high.
Is Illumina, Inc. profitable?
Yes. Illumina, Inc. keeps 19.72% of revenue as net income over the trailing twelve months.
What is the analyst price target for ILMN?
Wall Street analysts rate ILMN Buy, with an average price target of $252.73, 18.7% above the current price.
What sector is Illumina, Inc. in?
Illumina, Inc. is classified under the Healthcare sector and the Medical - Diagnostics & Research industry, and is domiciled in US.
Who is the CEO of Illumina, Inc.?
Jacob Thaysen is the chief executive of Illumina, Inc., which employs 8,600 people.
Where can I track ILMN in real time?
QFI Terminal shows ILMN with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See ILMN live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open ILMN in Terminal See plans